Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz and Indinavir Combination in HIV
NCT00002393Phase 3Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Placebo + Indinavir with Efavirenz + Indinavir (2 arms). Primary endpoint: Proportion of patients with HIV-RNA < 400 copies/mL at 24 weeks. Status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002393.